Glatt in Weimar, Germany has been commissioned to conduct a concept study to investigate the technical and economic aspects of a fill and finish plant for vaccines. The independent, fully integrated state-of-the-art biotechnological facility is to be built in Accra, Ghana.

The current pandemic has underscored the need for vaccine production in Africa. Through government’s vaccine development and manufacturing presidential committee (VMC), Ghanaian President Nana Addo Dankwa Akufo-Addo has convened a board to establish a 10-year plan for vaccine development and production. The most promising near-term approach to achieve this goal is the construction of a bottling and packaging plant, which will lay the foundation in the region for vaccine production against COVID-19 and other diseases.

As a process expert and working in close collaboration with the vaccine manufacturer, Glatt will provide detailed planning services for the plant, investigate its technical feasibility and provide economic efficiency advice.

In South Africa, Glatt is represented by Reitech SA.

Read the full article on Pharmaceutical & Cosmetic Review.